23 research outputs found
Audiologic monitoring of multi-drug resistant tuberculosis patients on aminoglycoside treatment with long term follow-up
<p>Abstract</p> <p>Background</p> <p>Multi-drug resistant tuberculosis has emerged as a significant problem with the resurfacing of tuberculosis and thus the need to use the second line drugs with the resultant increased incidence of adverse effects. We discuss the effect of second line aminoglycoside anti-tubercular drugs on the hearing status of MDR-TB patients.</p> <p>Methods</p> <p>Sixty four patients were put on second line aminoglycoside anti-TB drugs. These were divided into three groups: group I, 34 patients using amikacin, group II, 26 patients using kanamycin and group III, 4 patients using capreomycin.</p> <p>Results</p> <p>Of these, 18.75% of the patients developed sensorineural hearing loss involving higher frequencies while 6.25% had involvement of speech frequencies also. All patients were seen again approximately one year after aminoglycoside discontinuation and all hearing losses were permanent with no threshold improvement.</p> <p>Conclusion</p> <p>Aminoglycosides used in MDR-TB patients may result in irreversible hearing loss involving higher frequencies and can become a hearing handicap as speech frequencies are also involved in some of the patients thus underlining the need for regular audiologic evaluation in patients of MDR-TB during the treatment.</p
DIRECT DETERMINATION OF ZINC IN SERUM BY ZEEMAN ATOMIC-ABSORPTION SPECTROMETRY WITH A GRAPHITE-FURNACE.
Prospective, Randomized, Comparative-study of the Nephrotoxicity of Aminoglycosides in Humans
Prospective Comparative-study of the Nephrotoxicity of Aminoglycosides in Human (abstract)
HEMOPERFUSION-HEMODIALYSIS INEFFECTIVE FOR PARAQUAT REMOVAL IN LIFE-THREATENING POISONING
HEMOPERFUSION-HEMODIALYSIS INEFFECTIVE FOR PARAQUAT REMOVAL IN LIFE-THREATENING POISONING
HEMOPERFUSION-HEMODIALYSIS INEFFECTIVE FOR PARAQUAT REMOVAL IN LIFE-THREATENING POISONING
Oxidative Injury To Erythrocytes, Cell Rigidity and Splenic Hemolysis in Hemodialyzed Patients Before and During Erythropoietin Treatment
The oxidative injury to erythrocytes, red blood cell (RBC) rigidity and splenic hemolysis was assayed in 17 chronically hemodialyzed patients before and during recombinant erythropoietin (EPO) treatment. When a stable hematocrit between 30 and 35% had been established for at least 4 months, a statistically significant increase in RBC volume, hemoglobin concentration, hematocrit, reticulocyte count, and several RBC enzymes (2,3-diphosphoglycerate, glucose 6-phosphate dehydrogenase, pyruvate kinase, hexokinase) was noted. This indicated significant RBC rejuvenation under the influence of EPO. However, no significant improvement in the RBC oxidative sensitivity, RBC deformability, splenic RBC volume, slow mixing splenic RBC volume, and the intrasplenic RBC transit time could be disclosed. These data confirm the existence of an extraerythrocytic factor in uremic plasma, which is partly responsible for a reduced RBC life span in hemodialysis patients despite EPO treatment